Century Therapeutics (IPSC) Cash & Equivalents (2020 - 2026)

Century Therapeutics (IPSC) has 7 years of Cash & Equivalents data on file, last reported at $51.0 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents fell 1.58% year-over-year to $51.0 million in Q1 2026; TTM through Mar 2026 was $51.0 million, a 1.58% decrease from a year earlier, with the FY2025 full-year figure at $113.3 million, up 93.86% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $51.0 million, down from $113.3 million in the prior quarter.
• Over the last five years, Cash & Equivalents for IPSC reached as high as $126.0 million in Q1 2022 and fell as low as $41.5 million in Q2 2024.
• Historically, Cash & Equivalents has averaged $71.5 million across 5 years, with a median of $56.9 million in 2025.
• Across the five-year window, Cash & Equivalents plunged 58.58% in 2022 and jumped 93.86% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $84.3 million in 2022, then tumbled by 43.84% to $47.3 million in 2023, then gained by 23.49% to $58.4 million in 2024, then soared by 93.86% to $113.3 million in 2025, then slumped by 54.94% to $51.0 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $51.0 million in Q1 2026, $113.3 million in Q4 2025, and $55.5 million in Q3 2025.